245 related articles for article (PubMed ID: 2455700)
1. Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS).
Mandell LR; Ghavimi F; Exelby P; Fuks Z
Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):197-203. PubMed ID: 2455700
[TBL] [Abstract][Full Text] [Related]
2. Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy.
Mandell L; Ghavimi F; Peretz T; LaQuaglia M; Exelby P
J Clin Oncol; 1990 Sep; 8(9):1536-42. PubMed ID: 2391558
[TBL] [Abstract][Full Text] [Related]
3. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
4. Results of alternating chemotherapy and hyperfractionated radiation therapy in childhood rhabdomyosarcoma.
Merchant TE; Cahill JC; Ghavimi F
Med Pediatr Oncol; 1998 Jun; 30(6):332-8. PubMed ID: 9589081
[TBL] [Abstract][Full Text] [Related]
5. Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.
Dharmarajan KV; Wexler LH; Wolden SL
Pediatr Blood Cancer; 2013 Feb; 60(2):242-7. PubMed ID: 22619050
[TBL] [Abstract][Full Text] [Related]
6. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
[TBL] [Abstract][Full Text] [Related]
7. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
8. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
[TBL] [Abstract][Full Text] [Related]
9. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas.
Crist WM; Raney RB; Ragab A; Heyn R; Wharam M; Webber B; Johnston J; Beltangady M
Med Pediatr Oncol; 1987; 15(2):51-7. PubMed ID: 3587117
[TBL] [Abstract][Full Text] [Related]
11. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of rhabdomyosarcoma at the National Cancer Center Hospital].
Beppu Y; Fukuma H; Chuma H; Ise T; Ohira M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1603-13. PubMed ID: 3592704
[TBL] [Abstract][Full Text] [Related]
13. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
14. [Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer].
Hasbini A; Le Péchoux C; Roche B; Pignol JP; Zelek L; Abdulkarim B; Arriagada R; Guinebretière JM; Tardivon A; Spielmann M; Habrand JL
Cancer Radiother; 2000; 4(4):265-73. PubMed ID: 10994390
[TBL] [Abstract][Full Text] [Related]
15. The Intergroup Rhabdomyosarcoma Study-II.
Maurer HM; Gehan EA; Beltangady M; Crist W; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J
Cancer; 1993 Mar; 71(5):1904-22. PubMed ID: 8448756
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma.
Wolden SL; La TH; LaQuaglia MP; Meyers PA; Kraus DH; Wexler LH
Cancer; 2003 Jan; 97(1):179-85. PubMed ID: 12491519
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary elaboration of the method of complex treatment of rhabdomyosarcoma].
Bozek J; Czerwiński W; Woźniak W
Probl Med Wieku Rozwoj; 1984; 13():154-63. PubMed ID: 6549411
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.
Taylor RE; Howman AJ; Wheatley K; Brogden EE; Large B; Gibson MJ; Robson K; Mitra D; Saran F; Michalski A; Pizer BL
Radiother Oncol; 2014 Apr; 111(1):41-6. PubMed ID: 24630538
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma.
Regine WF; Fontanesi J; Kumar P; Zeitzer K; Greenwald C; Bowman L; Shapiro DN; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):799-805. PubMed ID: 7860391
[TBL] [Abstract][Full Text] [Related]
20. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
